Jefferies upgrades Tempus AI to Hold from Underperform, raises price target to $70 from $35
Jefferies upgraded Tempus AI to 'Hold' from 'Underperform' and raised its price target to $70 from $35, implying a 10.8% downside from the Nov 2 close of $78.48. Recent analyst price targets for Tempus AI range from $68 to $100.
How this was made
The 30-second read
Why it matters
The analyst's target raise signals confidence in the company's growth prospects, but the Hold rating suggests caution.
Market read
New analyst action provides fresh guidance for traders evaluating TPU.
What to watch
Recent earnings or pipeline updates not mentioned could affect the stock's trajectory.
Background
Tempus AI is a Nasdaq‑listed AI‑driven healthcare data company whose recent share price sits near $78.48.
Market effects
The upgrade may lift sentiment in the AI‑driven healthcare analytics niche.
Limited to U.S. investors focused on small‑cap biotech/AI stocks.
Minimal global impact beyond niche investors.
Counterpoint
The Hold rating tempers enthusiasm; the stock may still be overvalued at $78.48.
Key entities
- AnalystJefferies
Equity research firm issuing the upgrade and target raise.
- CompanyTempus AI
AI‑driven healthcare data platform.
